A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial
Sponsor: Pfizer
Terminated
Sponsor decision to terminate study based on results of parent study GBT2104-131.
Other terminated trials from Pfizer
Other Sickle Cell Disease trials with similar outcome
Listed as NCT05348915, this PHASE3 trial focuses on Sickle Cell Disease and Vaso-occlusive Crisis and remains terminated or withdrawn. Sponsored by Pfizer, it has been updated 24 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
24 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Nov 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 19 earlier versions
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE3
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE3
-
Mar 2025 — May 2025 [monthly]
Active Not Recruiting PHASE3
-
Dec 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
-
Oct 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE3
-
Feb 2024 — Apr 2024 [monthly]
Recruiting PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE3
-
Oct 2023 — Dec 2023 [monthly]
Recruiting PHASE3
Status: Enrolling By Invitation → Recruiting
-
Aug 2023 — Oct 2023 [monthly]
Enrolling By Invitation PHASE3
-
Mar 2023 — Aug 2023 [monthly]
Enrolling By Invitation PHASE3
-
Dec 2022 — Mar 2023 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Enrolling By Invitation PHASE3
-
May 2022 — Sep 2022 [monthly]
Enrolling By Invitation PHASE3
First recorded
Mar 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .